Artax Biopharma Raises $10M Series B to fund Phase Ib-IIa clinical trials for AX-024, a novel oral treatment for autoimmune diseases and to further develop its pipeline of preclinical candidates.

CAMBRIDGE, MASSACHUSETTS – September 22, 2015 – Artax Biopharma, a clinical stage biotechnology company developing first-in-class highly selective oral therapies for the treatment of autoimmune diseases, has secured a $10M Series B round of funding. The financing was...